Notícias

The new solar farms boost Matrix’s Spanish portfolio, supporting grid reliability and long-term clean power supply.

Insightful Moves in the First Quarter of 2026

By Twesha Dikshit, Avinash P and Johann M Cherian May 13 (Reuters) - European shares ended higher on Wednesday, led by gains in mining stocks, though caution lingered as investors weighed the economic

Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.

Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised its full-year outlook after stronger momentum late in the quarter. Group Chief Executive Officer Kai

Find insight on Merck KGaA, IHH Healthcare and more in the latest Market Talks covering the health care sector.

Merck overview and recent performance snapshot Merck (MRK) stock is drawing attention after a stretch of mixed returns, with a gain of 0.98% over the past day but declines of 0.69% over the past week and 7.45% over the past month. See our latest analysis for Merck. At a share price of $112.37, Merck’s short term share price momentum has cooled after a weaker 30 day share price return, even though its 1 year total shareholder return of 51.97% remains strong. If you are comparing Merck’s...

Will a hantavirus outbreak offset the regulatory risks weighing on Moderna stock? The path to recovery is far from certain.

Will a hantavirus outbreak offset the regulatory risks weighing on Moderna stock? The path to recovery is far from certain.

With an annual dividend yield of 3.06%, Merck & Co., Inc. (NYSE:MRK) is included among the 12 Best Blue Chip Dividend Stocks to Buy Now. Merck & Co., Inc. (NYSE:MRK) is a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies, and animal health products. On May 7, Citi analyst […]

Few stocks have polarized investors in 2026 like Eli Lilly (NYSE:LLY). After a stunning Q1 earnings report and raised full-year guidance, the question is whether the valuation has run ahead of fundamentals. Here is where I land on the $1,000 debate. The 24/7 Wall St. Price Target for Eli Lilly Eli Lilly trades at $948.45 as ... Eli Lilly Price Prediction: This Is Where The Stock Will End This Year

MRNA's Q1 revenues soar 260% on strong international vaccine sales, while cost cuts and new EU approvals support its broader growth strategy.

Merck (NYSE:MRK) is expanding clinical work around KEYTRUDA through a new collaboration with Erasca on ERAS-0015 in RAS-mutant solid tumors. Merck and Inhibrx reported positive interim Phase 2 data for INBRX-106 plus KEYTRUDA in head and neck cancer, with plans to move into Phase 3. These updates signal further external partnerships around KEYTRUDA combinations, adding to Merck's oncology pipeline as key patents approach expiry. For investors watching large pharma, Merck's focus on...

UNH, MRK and QCOM drew focus as analysts highlighted growth drivers, pipeline strength and expanding AI and automotive opportunities.

UnitedHealth, Merck and QUALCOMM lead Zacks' top research picks as analysts highlight growth drivers, earnings trends and key risks.

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the

Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.

Shareholders appeared unconcerned with Merck & Co., Inc.'s ( NYSE:MRK ) lackluster earnings report last week. Our...

Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the best performing healthcare stocks so far in 2026. On April 30, Mizuho reaffirmed an Outperform rating on Enliven Therapeutics, Inc. (NASDAQ:ELVN), setting a price target of $45. The rating update came after Merck noted during its fiscal Q1 earnings call that it believes Terns’ TERN-701 major molecular […]

The average American household spends about $519 a month on groceries, based on the latest BLS Consumer Expenditure Survey figure of $6,224 a year, and grocery prices are still rising: food-at-home prices were up 1.9% year over year as of March 2026. Add about $280 for utilities and roughly $100 for phone and internet, plus ... A $185,000 Portfolio That Covers Your Groceries, Utilities, and Phone Bill Every Month

Merck (NYSE:MRK) reported progress on its investigational oral PCSK9 inhibitor, enlicitide decanoate, including a biocatalytic large-scale manufacturing method. The company highlighted this new synthesis platform as a potential template for more sustainable macrocyclic peptide production. Separately, Merck faces an upcoming high profile trial concerning the safety of Gardasil, its widely used HPV vaccine. For investors watching NYSE:MRK, these updates sit alongside a stock that is priced at...

The stock has rapidly outpaced the broader market, but the long-term implications of the hantavirus are unclear.

Merck heads toward a July 27 Gardasil trial while defending the HPV vaccine's safety record.

They can weather many storms.

Moby summary of Codexis, Inc.'s Q1 2026 earnings call

An $83,400 annual paycheck sits comfortably above the U.S. median household income of roughly $80,610. Replacing that income with a portfolio, no employer required, is the question this article answers. The basic formula is income target divided by yield equals capital required. The more important issue is what changes across three yield tiers, and why ... A $1.5 Million Portfolio That Quietly Pays You $83,400 a Year, No Job Required